TOTAL: $20M
Year to Date: $492.87M

Company
(Symbol)#*

Partner
(Country)

Amt.
(M)

Triggering
Event

Details (Date)


Active Biotech
AB
(Sweden;
SSE:ACTI)
(Israel)

Teva Pharmaceutical Industries Ltd.

ND

Milestone payment

Triggered by positive results from a Phase IIb trial of laquinimod in patients with multiple sclerosis (9/5)

AnorMED Inc.
(Canada; ANOR)

Shire Pharmaceuticals Group plc (UK)

$3

Milestone payment

Triggered by Shire gaining approval in Germany to market Fosrenol for treating high phosphate levels in the blood (9/18)

Array
BioPharma
Inc.
(ARRY)

AstraZeneca plc (UK)

$3

Milestone payment

Triggered upon initiation of a Phase II trial of AZD6244 (ARRY-142886), a selective MEK inhibitor, in advanced melanoma patients (9/14)

Codexis Inc.*

Schering-Plough Corp.

ND

Milestone payment

Triggered by progress in deal to generate a biocatalytic process for producing an inter- mediate for an undisclosed therapeutic compound (9/11)

Inex
Pharmaceuticals
Corp.
(Canada;
TSX:IEX)

Hana Biosciences Inc. (HNAB)

$1

Milestone payment

Triggered by Hana's initiation of Phase I trials of INX-0125 (sphingosomal vinorelbine) for treating advanced solid tumors (8/30)@

Memory
Pharmaceuticals
Corp.
(MEMY)

Amgen Inc. (AMGN)

$2

Milestone payment

Triggered by preclinical progress in effort to develop PDE10 inhibitors for treating certain neurological and psychiatric disorders (9/28)

Pharmacopeia
Drug Discovery
Inc.
(PCOP)

Organon (the Netherlands)

ND

Milestone payment

Triggered by Pharmacopeia's delivery of two lead compound series, one for pain indications and one for obesity (9/19)

Pharmacopeia
Drug Discovery
Inc.
(PCOP)

Schering-Plough Corp.

ND

Milestone payment

Triggered by Schering's initiation of a Phase I trial of a compound identified in their cancer- focused collaboration (9/11)

Rigel
Pharmaceuticals
Inc.
(RIGL)

Serono SA (Switzerland; NYSE:SRA)

$3

Milestone payment

Triggered by Serono's initiation of a Phase I trial of R763 in patients with refractory solid tumors (9/19)

Scolr Pharma
Inc.
(AMEX:DDD)

Wyeth

ND

Milestone payment

Milestone was reached under 2005 deal in which Wyeth is investigating Scolr's delivery platform for use in an OTC formulation; Wyeth also agreed to reimburse Scolr for certain R&D costs already incurred (9/26)

Trubion
Pharmaceuticals
Inc.*

Wyeth

$8

Milestone payment

Triggered by initiation of a Phase II trial of TRU-015 for rheumatoid arthritis; the $8M payment includes reimbursement of prior manufacturing-related costs (9/27)


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Private company.

@News occurred in August but was not included in the previous chart.

Currency conversions are based on exchange rates at the time of the deal.

ND = Not disclosed.

AMEX = American Stock Exchange; NYSE = New York Stock Exchange; SSE = Stockholm Stock Exchange; TSX = Toronto Stock Exchange.

No Comments